Raptor Pharmaceuticals Corp. Report issue

For profit Phase 1 Phase 2
Founded: Novato CA United States (2005)
Status: Acquired by Horizon Pharma (2016) → now Amgen

Organization Overview

First Clinical Trial
2008
NCT00661141
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Raptor Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

Key: Raptor Pharmaceuticals Corp. (2) Acquired (2)

cysteamine (cystagon) (2 trials)

fomepizole (antizol) (1 trial)

ngx267 (1 trial)

tezampanel (1 trial)

Drugs in Phase 1 Trials (1)

Key: Raptor Pharmaceuticals Corp. (0) Acquired (1)

ngx426 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5